Related Experiment Video

Updated: Mar 16, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.6K

Cardiovascular safety of anti-diabetic drugs

R Kumar1, D M Kerins2, T Walther3

  • 1Department of Pharmacology and Therapeutics, University College Cork, Ireland rajesh.kumar@ucc.ie.

European Heart Journal. Cardiovascular Pharmacotherapy
|August 18, 2016
PubMed

Insights

Choosing diabetes medications that protect against cardiovascular disease is crucial, as heart conditions are the leading cause of death for diabetic patients. This review examines anti-diabetic drugs for their cardiovascular safety and impact.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is the primary cause of death in patients with diabetes mellitus.
  • Despite blood pressure and lipid management, most type 2 diabetes patients succumb to cardiovascular causes.
  • The co-occurrence of diabetes and cardiovascular disease, including heart failure, is rapidly increasing.

Purpose of the Study:

  • To review the efficacy and safety of commonly prescribed anti-diabetic drugs.
  • To assess the cardiovascular impact of these medications in diabetic patients.
  • To guide the selection of anti-diabetic therapies with favorable cardiovascular profiles.

Main Methods:

  • Systematic review of clinical trials and epidemiological studies.
  • Analysis of cardiovascular outcomes associated with various anti-diabetic drug classes.
  • Evaluation of drug safety profiles, particularly regarding side effects in heart failure patients.

Main Results:

  • Certain anti-diabetic medications demonstrate cardiovascular benefits, reducing event risk.
  • Other agents may increase cardiovascular risk or show neutral effects.
  • Diabetic patients with heart failure exhibit differential responses and increased susceptibility to side effects with standard treatments.

Conclusions:

  • Careful selection of anti-diabetic drugs is essential for optimizing patient outcomes.
  • Prioritizing cardiovascular safety in drug choice is paramount for managing diabetic patients.
  • Further research is needed to fully elucidate the cardiovascular effects of all anti-diabetic agents.

Keywords:
Anti-diabetic agentsCardiovascular diseaseDiabetes mellitus

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

715

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
753
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
238